Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
glaxosmithkline
25
×
life sciences
national blog main
san francisco blog main
national top stories
biotech
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
boston blog main
boston top stories
new york top stories
san diego blog main
san diego top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
national
seattle blog main
seattle top stories
texas blog main
texas top stories
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
clinical trials
fda
startups
amgen
deals
eli lilly
gene therapy
abbvie
biogen
bristol-myers squibb
cancer
merck
What
roundup
bio
drug
new
company
cancer
crispr
medical
days
giant
glaxosmithkline
news
pharmaceutical
adds
announced
arthritis
biotech
ceo
companies
conduct
devices
disease
drugs
firm
gsk
health
life
medicines
million
percent
therapeutics
year
abbvie’s
alliance
alphabet
apple
apple’s
big
bioelectronic
bioelectronics
Language
unset
unknown
Current search:
glaxosmithkline
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
ResMed Boosts Connected Health Play With $225M Propeller Health Deal
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Verana Health Lands $30M Financing Led By GV, Adds Miki Kapoor as CEO
@engadget.com
5 years ago
GSK to use 23andMe’s DNA library in drug development
@techcrunch.com
7 years ago
GlaxoSmithKline and Google’s life science wing form new bioelectronic medicine company
@theverge.com
7 years ago
GlaxoSmithKline and Google team up to create new bioelectronics health company
@techcrunch.com
7 years ago
GlaxoSmithKline taps Apple’s ResearchKit for an arthritis study
@theverge.com
7 years ago
Apple partners with pharmaceutical giant GlaxoSmithKline for first clinical study
@extremetech.com
8 years ago
Drug company reneges on promise to reverse 5,400-percent price hike on Daraprim